Varied Outcomes Predicted On Icahn's Bid For Four Seats On Genzyme's Board
This article was originally published in The Pink Sheet Daily
Executive Summary
Activist investor Carl Icahn seeking the kind of gains similar to those he realized at Biogen Idec.
You may also be interested in...
As Chinese and Indian Markets Expand, Young American Drug Outfits Should Hold Onto Ex-U.S. Rights, Says Genzyme Leader
BOSTON - Despite conventional wisdom and Wall Street's old-fashioned point of view, young American companies starting out should think long and hard before giving up ex-U.S. rights to their discoveries, the top executives of Massachusetts biotechs Genzyme and Biogen Idec advise
Hang On To Those Ex-U.S. Rights, Biotech Veterans Termeer And Mullen Advise Start-Ups
The two 30-year industry veterans talked about lessons learned, regulatory climate change and health care reform at MassBio's annual meeting in Boston.
Hang On To Those Ex-U.S. Rights, Biotech Veterans Termeer And Mullen Advise Start-Ups
The two 30-year industry veterans talked about lessons learned, regulatory climate change and health care reform at MassBio's annual meeting in Boston.